Thyrotropin alfa


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Adjunctive diagnostic tool w/ serum thyroglobulin testing in post-thyroidectomy patients for remnant thyroid tissue; Adjunct for thyroid remnant ablation 2 doses of 0.9 mg at 24-hr interval.
Dosage Details
Intramuscular
Adjunct to radioiodine for thyroid remnant ablation, Adjunctive diagnostic tool with serum thyroglobulin testing in post-thyroidectomy patients for remnant thyroid tissue
Adult: 2 doses of 0.9 mg at 24-hr interval into the gluteal muscle of post-thyroidectomy patients.
Reconstitution
Add 1.2 mL of sterile water for inj in a vial containing 1.1 mg to provide a soln containing 0.9 mg/mL.
Special Precautions
Patient w/ significant residual thyroid tissue, cardiac disease, extensive metastases, serious underlying illness, risk of stroke (e.g. history of migraine headaches, smoker), women on oral contraceptives. Pregnancy and lactation.
Adverse Reactions
Significant: Transient increase in serum thyroid hormone, stroke or symptoms predictive of stroke (e.g. unilateral weakness); enlargement of residual thyroid tissue or metastases causing pain and acute symptoms (depending on the location).
Nervous: Dizziness, fatigue, headache, asthenia, flu-like illness, paraesthesia, insomnia, tremors.
CV: Palpitations.
GI: Nausea, vomiting, diarrhoea.
Resp: Nasopharyngitis.
Musculoskeletal: Back pain.
Dermatologic: Hyperhidrosis.
Others: Discomfort at inj site.
Potentially Fatal: Drug-induced hyperthyroidism.
IM/Parenteral: C
Patient Counseling Information
This drug may cause dizziness and headache, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor neurologic adverse events (e.g. hemiplegia, hemiparesis, stroke, weakness), dyspnoea, dysphonia, stridor, or other symptoms of local tumour growth.
Overdosage
Symptoms: Nausea, weakness, dizziness, headache, vomiting, hot flashes. Management: Supportive treatment.
Action
Description: Thyrotropin alfa, a recombinant human TSH, binds to TSH receptors on thyroid epithelial cells stimulating iodine uptake and organification, and synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3) and thyroxine (T4).
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 3-24 hr.
Excretion: Elimination half-life: 25±10 hr.
Storage
Store between 2-8°C. Protect from light.
ATC Classification
H01AB01 - thyrotropin alfa ; Belongs to the class of thyrotropin. Used in anterior pituitary lobe hormone and analogue preparations.
References
Anon. Thyrotropin alfa. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com . Accessed 04/05/2017.

Buckingham R (ed). Thyrotrophin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/05/2017.

Joint Formulary Committee. Thyrotropin alfa. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/05/2017.

Thyrogen Injection, Powder, For Solution (Genzyme Therapeutics). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/05/2017.

Disclaimer: This information is independently developed by MIMS based on Thyrotropin alfa from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in